Donaldson Company heads into its June 2 fiscal Q3 earnings release with options traders unusually bullish — but short sellers quietly adding pressure from the other side.
The clearest divergence is in options positioning. The put/call ratio has dropped to 0.40, nearly a full standard deviation below its 20-day average of 0.48. That reading points to call-heavy activity — investors are not hedging into this print. They are reaching for upside. The contrast with a stock that has lost nearly 7% over the past month is worth noting. DCI closed at $81.87, down 1.8% on the day and 2.1% on the week, leaving it well below the mean analyst price target of $96.40.
Short interest tells a more cautious story beneath that bullish options surface. Bearish positioning has climbed roughly 30% over the past month, reaching 2.9% of the free float — still a modest absolute level, but the direction of travel is unambiguous. ORTEX's short score has crept from 37.2 to 38.9 over the past two weeks, a steady if unremarkable build. Borrow conditions remain loose: availability is running at over 2,200% of outstanding short interest, and the cost to borrow is just 0.51% annually. There is no squeeze dynamic here. Short sellers face no friction adding to positions.
The bull case rests on Life Sciences momentum and the company's demonstrated quality profile. Fiscal 2025 revenue hit $3.7 billion, with Life Sciences up 13% year-over-year. Forward EPS estimates are trending higher on both 30- and 90-day windows, and the dividend score ranks in the 99th percentile. Bulls can also point to a consensus price target implying roughly 18% upside from current levels, with Jefferies maintaining a Buy and a $123 target. Bears, however, focus on cyclical headwinds: Aerospace and Defense faces tough comparisons after a record fiscal 2025, and Donaldson's core mobile end markets — construction, agriculture, mining — remain under capital expenditure pressure. Baird trimmed its target from $104 to $95 in late March while keeping its Outperform rating, and Morgan Stanley nudged its Equal-Weight target to $91 from $93 around the same time. The analyst community has been quietly marking down expectations without abandoning the stock. Note that the most recent analyst changes are from late March, now about two months old.
The last quarterly print on February 26 was punishing — the stock fell 11.2% on the day and extended to a 12.2% decline over the following five sessions. Correlated peers have also been under pressure recently, with ERII down 5.3% on the day and TWI off 2% on the week, suggesting the broader industrial tape offers little buffer. With insider activity running net negative across the 90-day window — over $3.5 million in aggregate sales — and short positions building into a stock already bruised by its last report, the June 2 print is a direct test of whether Life Sciences and aftermarket resilience can offset the cyclical drag that spooked the market three months ago.
See the live data behind this article on ORTEX.
Open DCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
